At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 83 enrolled
Drug / intervention
Nab-paclitaxeldrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II, Open-label, Non-randomized Study of Nab-paclitaxel for the Neoadjuvant Treatment of Patients With Stage II and III Luminal Breast Cancer
In Brief
A Phase 2 clinical trial evaluating Nab-paclitaxel for Breast Cancer. Completed, enrolled 83 participants across 13 sites.
Detailed Summary
Multicenter, open label, non-randomized phase 2 trial to evaluate the efficacy and safety of nab-paclitaxel in the neoadjuvant treatment of ER positive human epidermal growth factor receptor 2 (HER2) negative patients amenable to receive neoadjuvant chemotherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesSpain
CollaboratorsCelgene
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMar 2012
Enrollment StartApr 2012
Primary CompletionJun 2014
Study CompletionMay 2018
TodayJul 2026
First PostedMar 28, 2012
Enrollment StartApr 17, 2012
Primary CompletionJun 1, 2014
Study CompletionMay 27, 2018
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 14.3 years ago
Interventions
Nab-paclitaxeldrug